Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
- Conditions
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT01897480
- Locations
- 🇩🇰
Herlev and Gentofte Hospital, Herlev, Hovedstaden, Denmark
🇫🇷CHU de Caen Hopital Cote de Nacre, Caen, France
🇫🇷CHU De Grenoble Hopital Albert Michallon, Grenoble Cedex 09, France
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 224
- Registration Number
- NCT01887795
- Locations
- 🇨🇳
Zhenzhou-Yang, Chongqing, Chongqing, China
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT01887886
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2023-01-19
- Target Recruit Count
- 43
- Registration Number
- NCT01859026
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 59
- Registration Number
- NCT01822496
- Locations
- 🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Baptist Medical Center South, Jacksonville, Florida, United States
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 138
- Registration Number
- NCT01801111
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸UCLA Cancer Center; Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
🇺🇸Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States
The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Wu Jieping Medical Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT01796288
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 338
- Registration Number
- NCT01782690
- Locations
- 🇩🇪
Klinikum der Universität zu Köln Klinik für Gastroenterologie am Abdominalzentrum, Köln, Germany
Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Wu Jieping Medical Foundation
- Target Recruit Count
- 210
- Registration Number
- NCT01763385
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2012-12-19
- Target Recruit Count
- 120
- Registration Number
- NCT01752205
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.